- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03518294
NASH Fitness Intervention in Thrombosis Trial (NASHFit)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
- Penn State Hershey Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria Adults age >=18 or <70 years Liver biopsy <= 6months prior to enrollment Biopsy proven NASH(79)
Lack of secondary causes of hepatic fat accumulation:
Significant alcohol consumption (<21 drinks/week for men and <14 drinks/week for women) Chronic hepatitis C Wilson disease Lipodystrophy Parenteral nutrition Long-term use of steatogenic medications (mipomersen, lomitapide, amiodarone, methotrexate, tamoxifen, corticosteroids) Monogenic hereditary disorders
Exclusion Criteria >90 minutes/week of at least moderate intensity exercise over the previous three months Pregnancy BMI <18 or >40 kg/m2(16) Uncontrolled diabetes (changes in medication dosing over the previous three months or hemoglobin A1c >9%)(12) Active cardiac symptoms Severe medical comorbidities/psychiatric illness Decompensated cirrhosis (history of esophageal varices, ascites or hepatic encephalopathy) Abdominal hernia Cancer with life expectancy <6 months MRI contraindications (severe claustrophobia, implanted ferrous metal) Other liver disease (positive hepatitis B surface antigen, antinuclear antibody titer >1:160) Active weight-loss program participation or weight-loss supplement use Active substance abuse/smoking Inability to provide informed consent Institutionalized/prisoner Inability to walk > 2 blocks or ¼ mile. Physical Activity Readiness Questionnaire (PAR-Q) score >=1 at the discretion of the study PI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Standard of Care
Subjects in the control condition will be instructed to continue their medical care at the discretion of their treating medical professional.
They will be informed to maintain their current physical activity level.
Weekly phone calls will be performed by study personnel to ensure adherence to the protocol (no changes in activity).
Subjects will report to Penn State on a monthly basis for anthropometric assessment to confirm their self-reports and study investigators will perform and interim history and physical examination at that time.
|
|
Experimental: Aerobic Exercise
Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity.
Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center.
Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
|
Subjects in the aerobic exercise group will be supervised to exercise 30 minutes, 5 times per week at a moderate intensity.
Formal exercise instruction and supervision will be provided by ACSM certified fitness professionals at the Penn State University Fitness Center.
Aerobic exercise can be completed on either the treadmill, exercise bike, rowing machine or the elliptical machine.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PAI-1 Level
Time Frame: 5 months
|
Change in fibrinolysis as indicated by PAI-1 level was calculated by taking the difference of measurements at baseline and 5 months.
|
5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Von Williebrand Factor (vWF)
Time Frame: 5 months
|
Change in vWF was calculated by taking the difference of measurements at baseline and 5 months.
|
5 months
|
Change in Protein S
Time Frame: 5 months
|
Change in protein S was calculated by taking the difference of measurements at baseline and 5 months.
|
5 months
|
Change in Factor VIII
Time Frame: 5 months
|
Change in factor VIII was calculated by taking the difference of measurements at baseline and 5 months.
|
5 months
|
Change in Fibrinogen
Time Frame: 5 months
|
Change in fibrinogen was calculated by taking the difference of measurements at baseline and 5 months.
|
5 months
|
Change in Antithrombin
Time Frame: 5 months
|
Change in antithrombin was calculated by taking the difference of measurements at baseline and 5 months.
|
5 months
|
Change in Protein C
Time Frame: 5 months
|
Change in protein C was calculated by taking the difference of measurements at baseline and 5 months.
|
5 months
|
Change in Adiponectin
Time Frame: 5 months
|
Change in adipontin was calculated by taking the difference of measurements at baseline and 5 months.
|
5 months
|
Patatin Like Phospholipase-3 (PNPLA3) rs738409 Polymorphism
Time Frame: 5 months
|
Patatin like phospholipase-3 (PNPLA3) rs738409 polymorphism genotyping subjects (GG, GC and CC genotypes)
|
5 months
|
Change in PAI-1 Stratified by Fibrosis Stage
Time Frame: 5 months
|
Change is the difference between measurements at baseline and 5 months
|
5 months
|
Change in % Hepatic Fat
Time Frame: 5 months
|
Change in % hepatic fat was calculated by taking the difference of measurements at baseline and 5 months.
|
5 months
|
Health Related Quality of Life (HRQOL) Change
Time Frame: 5 months (20 weeks)
|
Data was collected at baseline and at 5 months to assess changes in domains of health. PROMIS-29 Profile v2.1 (Physical function & pain interference) PROMIS Bank v2.0 - Instrumental Support (Social Support) Scores are reported as standardized T-score metrics derived from population means, with a mean of 50 and standard deviation of 10. The minimum is 0 and the maximum is 90. A higher score for fatigue, pain intensity, pain interference, sleep disturbance, anxiety and depression means a worse outcome. A higher score for physical function and social roles means a better outcome. |
5 months (20 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jonathan Stine, MD, Milton S. Hershey Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8507
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Diseases
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
-
Beijing Friendship HospitalUnknownNonalcoholic Fatty Liver Disease | Liver Steatosis | Liver FibrosisChina
-
Institute of Liver and Biliary Sciences, IndiaCompletedAcute Liver FailureIndia
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Medical College of WisconsinRecruiting
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
Beijing Continent Pharmaceutical Co, Ltd.RecruitingAcute-On-Chronic Liver Failure | Acute Liver FailureChina
-
Johannes Gutenberg University MainzUniversity of JenaCompletedNon-alcoholic Fatty Liver Disease | Fatty Liver, NonalcoholicGermany
-
The Cleveland ClinicCompleted
Clinical Trials on Aerobic Exercise
-
Riphah International UniversityCompleted
-
Sultan Abdulhamid Han Training and Research Hospital...RecruitingPhysical InactivityTurkey
-
University of FloridaAmerican Psychological Foundation; Clinical & Translational Science Institute; American Psychological Association (APA)CompletedBrain ConcussionUnited States
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)TerminatedChildhood ObesityUnited States
-
Radboud University Medical CenterUniversity Hospital, Bonn; University of Dublin, Trinity College; German Sport... and other collaboratorsCompletedMild Cognitive ImpairmentNetherlands, Ireland, Germany
-
National Yang Ming UniversityUnknownKnee OsteoarthritisTaiwan
-
National Defense Medical Center, TaiwanMinistry of Science and Technology, TaiwanRecruitingCardiology | PsychiatryTaiwan
-
Federal University of PelotasMinistry of Health, BrazilUnknownHypertension | Cardiovascular Disease | Chronic Kidney Disease | Chronic Renal DiseaseBrazil
-
University of Kansas Medical CenterRecruiting
-
Lithuanian University of Health SciencesCompletedMigraine | Temporomandibular Joint Disorders | Myofascial Trigger Point PainLithuania